Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) recorded quarterly Gross Margin of 51.19% in Q1 2026, up 98.77% quarter-over-quarter from 25.75% in Q4 2025, and up 3470.0% on a YoY basis from 1.43% in Q1 2025.
Maravai Lifesciences Holdings (MRVI) Gross Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Gross Margin history runs 7 years deep, the most recent figure standing at 51.19% for Q1 2026.
- In Q1 2026, Gross Margin rose 3470.0% year-over-year to 51.19%; the TTM figure through Mar 2026 stood at 29.29% (down 800.0% YoY), while the FY2025 annual figure was 18.3%, down 2349.0% from the prior year.
- Gross Margin was 51.19% for Q1 2026 at Maravai Lifesciences Holdings, up from 25.75% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 84.55% in Q2 2022 to a low of 13.58% in Q3 2025.
- Historically, Gross Margin has averaged 47.27% across 5 years, with a median of 45.13% in 2023.
- The sharpest annual moves came in 2023 and 2026: Gross Margin slumped 4735 bps in 2023, then jumped 3470 bps in 2026.
- A 5-year view of Gross Margin shows it stood at 73.99% in 2022, then declined by 29 bps to 52.65% in 2023, then sank by 35 bps to 34.28% in 2024, then declined by 25 bps to 25.75% in 2025, then soared by 99 bps to 51.19% in 2026.
- The last three Gross Margin figures came in at 51.19% (Q1 2026), 25.75% (Q4 2025), and 13.58% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 79.04% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 737.25 Mn | 728.85 Mn | 33.70 Mn | 51.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.19% |
| Dec 31, 2025 | 25.75% |
| Sep 30, 2025 | 13.58% |
| Jun 30, 2025 | 16.39% |
| Mar 31, 2025 | 16.49% |
| Dec 31, 2024 | 34.28% |
| Sep 30, 2024 | 46.70% |
| Jun 30, 2024 | 44.42% |
| Mar 31, 2024 | 40.27% |
| Dec 31, 2023 | 52.65% |
| Sep 30, 2023 | 45.13% |
| Jun 30, 2023 | 37.21% |
| Mar 31, 2023 | 57.39% |
| Dec 31, 2022 | 73.99% |
| Sep 30, 2022 | 80.04% |
| Jun 30, 2022 | 84.55% |
| Mar 31, 2022 | 83.61% |
| Dec 31, 2021 | 82.87% |
| Sep 30, 2021 | 84.27% |
| Jun 30, 2021 | 82.64% |